Aspire Biopharma Holdings (ASBP) Return on Assets (2025 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Return on Assets came in at 0.03% in Q1 2026, up 13.0% year-on-year from 0.03% in Q1 2025, and up 76.96% on a QoQ basis from 0.14% in Q4 2025.
Aspire Biopharma Holdings (ASBP) Return on Assets (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 2 years of Return on Assets data on file, last reported at 0.03% in Q1 2026.
- On a quarterly basis, Return on Assets rose 13.0% year-over-year to 0.03% in Q1 2026; TTM through Mar 2026 was 0.03%, a 13.0% increase from a year earlier, with the FY2025 full-year figure at 0.26%, down 26.0% from the prior year.
- Return on Assets for Q1 2026 stood at 0.03%, up from 0.14% in the prior quarter.
- Over the last five years, Return on Assets for ASBP reached as high as 0.03% in Q1 2026 and fell as low as 0.16% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -0.69% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -0.01% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.80% |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 0.00% |
| 10 | Aspire Biopharma Holdings | 1.09 Mn | -733,865.14 | 5,750.00 | -0.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.03% |
| Dec 31, 2025 | -0.14% |
| Sep 30, 2025 | -0.11% |
| Jun 30, 2025 | -0.11% |
| Mar 31, 2025 | -0.16% |